NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization19.41 mln
Float15.89 mln
Earnings Date11/12/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
6.30
Extremely leveraged
Pre-Tax Margin
-3,575%
Severely loss-making
ROE
-139
Deeply negative
Altman Z-Score
-6.5
Deeply distressed
Business Description
Allarity Therapeutics is a Boston-based pharmaceutical company founded in 2004 that works to match cancer patients with treatments most likely to work for them. The company uses its own proprietary technology to predict how individual patients will respond to specific drugs, helping to guide more targeted treatment decisions. Its primary focus is Stenoparib, a cancer-fighting drug currently in a Phase 2 trial for women with advanced or recurring ovarian cancer, alongside a paired diagnostic tool designed to identify which patients are best suited for the treatment.
